Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.45 |
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | BRD2 | P25440 | 2/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.33 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28669450 | 0.83 | ADORA2A (0.40) | ADORA2ABRD4BRD2BRD3BRDT | |
| SCHEMBL5444381 | 0.82 | ADORA2A (0.39) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24476380 | 0.82 | CSNK2A1 (0.37) | ADORA2AP2RX7ADORA2B | |
| SCHEMBL31714921 | 0.81 | P2RX7 (0.34) | P2RX7YTHDC1 | |
| SCHEMBL28649295 | 0.81 | ADORA2A (0.38) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24476506 | 0.81 | ADORA2A (0.38) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24476329 | 0.81 | P2RX7 (0.33) | P2RX7 | |
| SCHEMBL24476543 | 0.81 | P2RX7 (0.33) | P2RX7 | |
| SCHEMBL24476664 | 0.81 | CSNK2A1 (0.36) | ADORA2AP2RX7ADORA2B | |
| SCHEMBL5838977 | 0.80 | ADORA2A (0.44) | ADORA2ABRD4BRD2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| EP-2498780-B1 | N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-09-07 | — | — | EP | disclosed |
| EP-2498780-B1 | N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| EP-1423390-A2 | PURINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | Bristol-Myers Squibb Company (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1383743-A2 | DUAL INHIBITORS OF PDE 7 AND PDE 4 | Bristol-Myers Squibb Company (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030104974-A1 | Dual inhibitorsof PDE 7 and PDE 4 | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-05 | — | — | US | disclosed |
| US-20030100571-A1 | Purine inhibitors of phosphodiesterase (PDE) | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002102314-A2 | PURINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002088079-A2 | DUAL INHIBITORS OF PDE 7 AND PDE 4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088080-A2 | DUAL INHIBITORS OF PDE 7 AND PDE 4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100571-A1 | Purine inhibitors of phosphodiesterase (PDE) | PDE7A, PDE7B, PDE3A | ADORA2A 125/4885BRD4 3243/4885BRD2 2539/4885 |
| US-20030104974-A1 | Dual inhibitorsof PDE 7 and PDE 4 | PDE4A, PDE4B, PDE7B | ADORA2A 1173/4885BRD4 284/4885BRD2 1695/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | ADORA2A 1445/4885BRD4 2248/4885BRD2 2907/4885 |
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885BRD4 3337/4885BRD2 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.